Laboratory Tests - CRD Patients — NCD 181 | CMS Coverage Update

TL;DR: The Centers for Medicare & Medicaid Services modified NCD 181 governing routine laboratory tests for chronic renal disease (CRD) patients on dialysis, effective March 7, 2026. If your facility bills for dialysis-related lab work, this policy defines exactly which tests get covered without additional documentation—and which ones require medical justification to avoid a claim denial.

---

Field	Detail
Payer	Centers for Medicare & Medicaid Services (CMS)
Policy	Laboratory Tests - CRD Patients
Policy Code	NCD 181
Change Type	Modified
Effective Date	March 7, 2026
Impact Level	High
Specialties Affected	Nephrology, Dialysis Facilities, Independent Laboratories, Hospital Outpatient
Key Action	Audit your lab order frequencies against the NCD 181 routine coverage schedule before March 7, 2026, and add medical justification documentation for any tests ordered above the covered frequency

---

CMS Routine Lab Coverage Criteria and Medical Necessity Requirements for CRD Dialysis Patients 2026

NCD 181 is the National Coverage Determination governing Medicare coverage of routine laboratory tests for chronic renal disease patients undergoing dialysis. The policy draws a hard line between "routine" tests—covered at defined frequencies without additional documentation—and "nonroutine" tests, which require medical justification tied to diagnosis.

That distinction matters enormously for your billing team. A routine test billed at a greater frequency than the policy allows becomes a nonroutine test in CMS's eyes. Without documented medical justification in the chart, you're looking at a claim denial. This is the most common way dialysis facilities bleed reimbursement on lab work—not because the tests aren't clinically appropriate, but because the documentation doesn't match the billing.

The coverage policy establishes four frequency tiers for routine tests. Each tier has specific tests assigned to it, and the frequency is the ceiling for automatic coverage. Going above that ceiling without justification is a billing liability, not a clinical decision.

Per Dialysis Session (no additional documentation required):
All hematocrit or hemoglobin tests and clotting time tests furnished incident to dialysis treatments are covered at this frequency. These are bundled into the routine dialysis monitoring protocol.

Per Week:

#	Covered Indication Copy
1	Prothrombin time — but only for patients on anticoagulant therapy. If your patient isn't on anticoagulants, weekly PT billing won't hold up.
2	Serum Creatinine

Per Week or 13 Times Per Quarter:

#	Covered Indication Copy
1	BUN (Blood Urea Nitrogen)

The "per week or 13 per quarter" language on BUN is slightly unusual and worth flagging. Thirteen weeks per quarter means the frequencies are essentially equivalent, but the quarterly cap gives CMS an audit benchmark. If your facility is billing more than 13 BUN tests in a calendar quarter, you need documented justification for each excess test.

Monthly:
CBC, Serum Calcium, Serum Potassium, Serum Chloride, Serum Bicarbonate, Serum Phosphorous, Total Protein, Serum Albumin, Alkaline Phosphatase, AST/SGOT, and LDH are all covered once monthly. That's 11 tests on a monthly cycle. If your order sets are generating these more frequently, your charge capture is creating exposure.

Every Three Months (Quarterly):

#	Covered Indication Copy
1	Serum Aluminum
2	Serum Ferritin

These two are specifically carved out as "tests other than those routinely performed," with one covered test allowed per three-month period. Quarterly, not monthly—get that into your order sets now.

The prior authorization requirements for NCD 181 are not explicitly stated in the policy—routine tests at covered frequencies don't require prior auth or additional documentation. But the moment a test crosses into nonroutine territory (wrong frequency, wrong indication, or outside the covered list), standard Medicare medical necessity documentation requirements apply.

---

CMS Hepatitis B Serologic Surveillance Coverage Policy for Dialysis Patients 2026

Hepatitis B testing for dialysis patients runs on a completely separate coverage framework within NCD 181, and it's one of the more complex pieces of this policy. Get it wrong and you'll either under-bill covered tests or generate denials on tests that weren't indicated.

When a patient first enters a dialysis facility, HBsAg and Anti-HBs testing are covered. After that initial screen, ongoing coverage depends on two factors: vaccination status and serologic status. The policy pays separately for these hepatitis B surveillance tests—they're explicitly excluded from the payment bundled into maintenance dialysis treatment rates, which means they should be billed separately on the claim.

The coverage matrix breaks down as follows:

Vaccination Status	Serologic Status	HBsAg Testing Frequency	Anti-HBs Testing Frequency
Unvaccinated	Susceptible	Monthly	Semiannually
Unvaccinated	HBsAg Carrier	Annually	None
Unvaccinated	Anti-HBs-Positive (≥10 SRUs)	None	Annually
Vaccinated	Anti-HBs-Positive (≥10 SRUs)	None	Annually
Vaccinated	Low Level or No Anti-HBs	Monthly	Semiannually

"Anti-HBs-Positive" under this policy means a level of at least 10 sample ratio units (SRUs) by radioimmunoassay (RIA) or positive by enzyme immunoassay (EIA). That threshold matters—if a patient tests below 10 SRUs, they don't qualify as Anti-HBs-Positive and the frequency schedule shifts accordingly.

Patients mid-vaccination series (haven't completed all three doses) should continue to be screened as susceptible. Between one and six months after the third dose, test for Anti-HBs to confirm vaccine response. If confirmed positive at ≥10 SRUs, the patient moves to annual Anti-HBs surveillance only. If they fall below 10 SRUs later, a booster dose is indicated—and the surveillance frequency resets.

Document the serologic status and vaccination stage in the chart every time you bill a hepatitis B surveillance test. These are paid separately from dialysis, but CMS auditors will pull the clinical record to verify the billing frequency matches the patient's documented status.

---

CMS CRD Lab Test Exclusions and Non-Covered Indications

NCD 181 doesn't label specific tests as experimental or investigational, but it effectively creates a two-tier exclusion structure through frequency caps and the routine/nonroutine distinction.

Any test on the covered list, billed above the stated frequency without documented medical justification, is treated as non-covered. This isn't a technicality—it's the primary denial trigger for dialysis lab billing. Monthly tests billed twice in a month, quarterly tests billed monthly, weekly tests billed for patients who don't meet the clinical criteria (anticoagulant therapy for PT, specifically)—all of these generate exposure.

Tests not on the routine list at all require diagnosis-based justification from the start. The policy is explicit: "Bills for other types of tests are considered nonroutine." CMS doesn't enumerate every nonroutine test that might be appropriate—it just requires that the diagnosis in the chart supports the test. If the ICD-10 code on the claim doesn't clearly connect to the test ordered, the denial follows.

Free-standing laboratories billing for dialysis patients face an additional requirement: the lab must meet Medicare's conditions of coverage for independent laboratories. If your facility uses an outside lab for some of these tests, verify their certification status before assuming the claim will pay.

---

Coverage Indications at a Glance

---

CMS CRD Lab Billing Guidelines and Action Items for Dialysis Facilities 2026

Copy Action Items

---

CPT, HCPCS, and ICD-10 Codes for CRD Routine Lab Tests Under NCD 181

NCD 181 as published does not enumerate specific CPT or HCPCS codes for the covered laboratory tests. The policy defines coverage by test name and frequency—not by billing code. This is intentional: CMS expects your billing team to apply the correct lab CPT codes from the standard code set and then validate coverage against the NCD 181 frequency and medical necessity criteria.

This is actually a practical problem. It means you can't rely on a simple code list to confirm coverage. You need to match the test name, the patient's clinical situation (e.g., anticoagulant therapy for PT), the billing frequency, and the medical justification to the policy framework. If you're not sure which CPT codes your lab is reporting for these tests—or whether those codes have been correctly mapped to the NCD 181 covered tests—run a cross-reference with your lab's superbill or encounter codes now.

No ICD-10-CM codes are specified in the policy data. The coverage policy relies on diagnosis-based justification for nonroutine tests, which means the ICD-10 codes you report on nonroutine lab claims need to clearly support the test ordered. CRD diagnosis codes (N18.x series for chronic kidney disease) are the expected primary diagnoses, but the specific ICD-10 mapping is clinical—confirm with your medical director for any nonroutine test documentation.

---